Wockhardt

    WOCKPHARMA
    Pharma
    ₹2,026.60
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹32,935 Cr

    P/E
    80.36
    Day range
    ₹2,005.00 – ₹2,065.00
    52-week range
    ₹1,086.70 – ₹2,422.30
    Volume
    7.26 L
    Open
    ₹2,018.30
    Prev close
    ₹2,008.90

    Latest results · Q2 FY27(consolidated)Revenue ₹969 Cr+23.9%Profit ₹73 Cr-11.0%Margin 7.5%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 48 / 100

    Factor percentiles

    Value27
    Quality40
    Momentum82
    Low volatility43

    Derived metrics

    Earn. yield
    1.2%
    Graham no.
    ₹420.62
    vs Graham
    -79.2%
    ROE ÷ P/B
    0.7%
    12-1 mom.
    +45.7%
    Return / vol
    1.01
    Magic Formula
    #592
    Piotroski
    5/6
    FCF yield
    0.1%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    WockhardtWOCKPHARMA₹32,935 Cr80.366.344.3%8.0%18.0%0.43+23.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1d ago

    Headlines about Wockhardt from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    81.7
    Price / Book
    6.39
    ROE (FY26)
    4.3%
    ROCE (latest year)
    8%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹1,931.67
    Price above
    50-day
    ₹2,041.76
    Price below
    200-day
    ₹1,735.87
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +8.4%
    Revenue YoY (Sep 2026)
    +23.9%
    Profit YoY (Sep 2026)
    -11.0%
    Operating margin
    18.0%
    Net margin
    7.5%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -500 Cr0 Cr500 Cr1K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026-25%0%25%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-40%-20%0%20%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY14FY15FY16FY17₹0₹5₹10₹15₹20

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales701700739809721743738782888965929969
    YoY Sales growth——————0-3————
    Expenses664759648699593679666604711740737796
    Operating Profit37-59911101286472178177225192173
    OPM %5%-8%12%14%18%9%10%23%20%23%21%18%
    Other Income810309815-772115673111
    Interest777373736048485560505256
    Depreciation555854555553565365535555
    Profit before tax-87-180-6-921-22-109916718911673
    Tax %-1%-2%167%78%5%105%-1%10%9%13%8%0%
    Net Profit-86-177-16-1620-45-108826116410773
    EPS in Rs₹-5.76₹-11.02₹-0.91₹-1.43₹0.86₹-1.54₹-5.54₹4.80₹3.63₹10.22₹6.52₹4.86

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days64

    -60 days since Mar 2021

    Inventory Days286

    +30 days since Mar 2021

    Days Payable182

    -41 days since Mar 2021

    Cash Conversion Cycle168

    +11 days since Mar 2021

    Working Capital Days35

    +168 days since Mar 2021

    Strengths, risks & growth

    Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 6.33 times its book value
    • The company has delivered a poor sales growth of 4.49% over past five years.
    • Company has a low return on equity of -1.43% over last 3 years.
    • Promoter holding has decreased over last 3 years: -5.81%

    Compounded Sales Growth

    10 Years
    -3%
    5 Years
    +4%
    3 Years
    +8%
    TTM
    +26%

    Compounded Profit Growth

    10 Years
    +1%
    5 Years
    -19%
    3 Years
    +43%
    TTM
    +629%

    Stock Price CAGR

    10 Years
    +12%
    5 Years
    +38%
    3 Years
    +83%
    1 Year
    +47%

    Return on Equity

    10 Years
    -2%
    5 Years
    -3%
    3 Years
    -1%
    Last Year
    +6%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter49.09%49.09%49.09%49.33%+0.24 pp
    FII7.00%7.09%7.23%7.02%-0.21 pp
    DII10.55%10.96%9.24%9.00%-0.24 pp
    Government0.02%0.04%0.02%0.01%-0.01 pp
    Public33.36%32.84%34.44%34.64%+0.20 pp

    Filed with NSE for Sept 2026: promoters 49.32%, public 50.68%

    Analysts & fund holdings

    Valuation vs Pharmaceuticals
    P/E80.4 vs 45.1
    Sector P/B6.03
    Beta1.26

    Who holds the shares, quarter by quarter

    Mutual funds 5.99% (-0.80 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters49.3%
    • Foreign institutions7.0%
    • Mutual funds6.0%
    • Insurance1.9%
    • Other domestic institutions1.1%
    • Retail19.2%
    • Others15.5%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Tata Small Cap Fund1.22%3.38%+0.13 pp
    HSBC Small Cap Fund0.69%1.30%-0.00 pp
    Tata Large & Mid Cap Fund0.57%2.70%+0.27 pp
    Invesco India Contra Fund0.38%0.65%+0.01 pp
    Bandhan Small Cap Fund0.30%0.28%-0.07 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 291 daily sessions to 17 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    49.6%
    Downside volatility
    38.9%
    Worst 5% of days
    3.9%
    Average of that tail
    6.1%
    Max drawdown (1Y)
    29.7%
    Below its peak
    13.8%

    Against the market

    Beta vs Nifty 50
    0.97
    Correlation
    0.27
    Relative strength (3M)
    -0.2%
    ATR (14)
    3.8%

    Return

    Return 1M
    +3.1%
    Return 3M
    +3.9%
    Return 6M
    +30.0%
    Return 1Y
    +50.2%
    vs 200-day average
    +15.7%

    Momentum

    RSI (14)
    53.2
    MACD histogram
    17.92
    Stochastic %K
    71.9
    ADX (14)
    18.0
    +DI / −DI
    22.0 / 19.4
    Money flow index
    57.2

    Participation

    Delivery (20d avg)
    37.5%
    vs its 60-day baseline
    -0.4 pts
    Volume vs 20-day
    -1.0σ
    Close vs day's VWAP
    -0.7%
    52-week position
    74 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹26 Cr
    FCF yield
    0.1%
    Cash conversion
    1.96
    Accruals ratio
    -0.022
    Net debt
    ₹1,908 Cr
    Net debt / equity
    0.37
    EV / sales
    9.21
    Capex intensity
    10.8%
    Revenue CAGR
    19.3%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Jun 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      7 Aug 2023
      ex-date
    • rights
      Not available — not reported in this filing

      Rights 3:10@ Premium Rs 220 Per Share

      8 Mar 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Jul 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      24 Jul 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      2 Aug 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      25 Jul 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      24 Jul 2017
      ex-date
    • dividend
      ₹10.00

      Interim Dividend Rs 10/- Per Share (Purose Revised)

      17 Nov 2016
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      4 Aug 2016
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Sept 2015
      ex-date
    • dividend
      ₹20.00

      Interim Dividend - Rs 20/- Per Share

      13 Nov 2014
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      4 Sept 2014
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Rs 5/- Per Share

      17 Feb 2014
      ex-date
    • dividend
      ₹5.00

      Interim Dividend Rs.5/- Per Share

      7 Nov 2013
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting / Dividend Rs.5 Per Share

      22 Aug 2013
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Sept 2012
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      30 Aug 2011
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      8 Sept 2010
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Jun 2009
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Pursuant to Regulation 30 of SEBI LODR Regulations, 2015 read with Schedule III thereto, we wish to inform you that Mr. Vinesh Kumar Jairath (DIN: 00391684) has completed his second consecutive ....

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Please refer the attachment.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Appointment of Mr. Sumit Garg as Chief Digital & Information Officer as Senior Management Personnel of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please refer the attachment.

    Result
    Quarter And Half Year Ended September 30, 2026.

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of directors at its meeting held today, i.e. 2nd November, 2026, inter-alia, ....

    Board Meeting
    Board Meeting Outcome for Financial Result For The Quarter And Half Year Ended September 30, 2026

    Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting ....

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    We wish to inform that Share Allotment Committee of Board of Directors of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant to exercise ....

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited ('The Company')

    Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement regarding the opening of special ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Certificate received from MUFG Intime India Private Limited, Registrar and ....

    Insider Trading / SAST
    Closure of Trading Window

    The Trading Window for dealing in the equity shares of the Company will be closed from 1st October, 2026 until 48 hours after the declaration of Unaudited financial results for quarter ....

    Others
    Disclosure under Regulation 30A of LODR

    Pursuant to Regulation 30 (read with Part A of Schedule III) of SEBI (LODR) Regulations 2015, we wish to inform you that the Company is in receipt of an Adjudication Order passed by Commissioner ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement published today i.e. 25th August, ....

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Please find enclosed herewith Scrutinizer's Report on the combined voting results of remote e-voting and e-voting during the 27th AGM of the Company

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, the Proceedings of the 27th AGM of the Company

    Filed with BSE (scrip 532300); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Regulatory orders

    • Adjudication order

      Adjudication order in respect of Crosseas Capital Services Ltd in the matter of trading in the Scrip of Wockhardt Ltd

      31 Jul 2023
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of three entities in the matter of Wockhardt Limited

      31 Jul 2023
      Read on SEBI
    • Final order

      Final Order in the matter of Wockhardt Ltd.

      19 Jun 2023
      Read on SEBI
    • Settlement order

      Settlement Order in respect of four entities in the matter of Wockhardt Limited

      22 May 2023
      Read on SEBI
    • Settlement order

      Settlement Order in respect of Vijay Khetan in the matter of Wockhardt Limited

      2 Mar 2023
      Read on SEBI

    Documents

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Wockhardt: common questions

    Answered from the figures on this page.

    Wockhardt last traded at ₹2,026.60 (NSE, as of 18 Nov 2026). The last session moved it up 0.88%.

    Wockhardt is valued at about ₹32,935 crore (NSE, as of 18 Nov 2026).

    Wockhardt trades at a price-to-earnings ratio of 80.36 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Wockhardt has traded between ₹1,086.70 and ₹2,422.30 over the past 52 weeks, to 18 Nov 2026. It is currently 70% of the way up that range.

    Wockhardt (WOCKPHARMA) is classified under Pharma on this site's screener.